clinical trial · NCT07203001
A Phase II Trial to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Pediatric and Adult Participants With Still's Disease
Still´s DiseaseMAS825
brief summary
The study is a phase II trial designed to evaluate the clinical efficacy, safety, and tolerability of MAS825 in pediatric and adult participants with Still's disease
started
Nov 3, 2025
primary completion
May 24, 2029
completion
May 24, 2029
last updated
Apr 21, 2026
official title
An Open-label Phase II Trial to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Pediatric and Adult Participants With Still's Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol